Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.

Hisamitsu IshiharaSusumu YamaguchiToshifumi SugitaniYoshinori Kosakai
Published in: Clinical drug investigation (2020)
ClinicalTrials.gov (NCT02847091).